Rxsight (RXST) closed at $5.02 on October 23, 2026, down 1.2% from the previous close, on volume of 311,317 shares (30-day average 717,954).
Data as of October 23, 2026.
23-Oct-2026
No headlines found.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Globe Newswire (Fri, 23-Oct 8:00 PM ET)
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
Globe Newswire (Tue, 20-Oct 4:05 PM ET)
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
Globe Newswire (Mon, 19-Oct 9:00 AM ET)
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
Globe Newswire (Fri, 16-Oct 12:00 PM ET)
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
Globe Newswire (Wed, 26-Aug 4:15 PM ET)
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Rxsight trades on the NASDAQ stock market under the symbol RXST.
As of October 23, 2026, RXST stock price declined to $5.02 with 311,317 million shares trading.
RXST has a beta of 0.86, meaning it tends to be less sensitive to market movements. RXST has a correlation of 0.03 to the broad based SPY ETF.
RXST has a market cap of $208.80 million. This is considered a Small Cap stock.
Last quarter Rxsight reported $34 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.12.
In the last 3 years, RXST traded as high as $66.54 and as low as $4.40.
The top ETF exchange traded funds that RXST belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
RXST has underperformed the market in the last year with a return of -40.5%, while the SPY ETF gained +14.3%. In the last 3 month period, RXST fell short of the market, returning -6.5%, while SPY returned +3.2%. However, in the most recent 2 weeks RXST has outperformed the stock market by returning +4.4%, while SPY returned -2.4%.
RXST support price is $4.91 and resistance is $5.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXST shares will trade within this expected range on the day.